GlassScriptPhysician profile
Brandy Marie Richards
NPI 1770037343
$7,977.51
in general payments reported to CMS, 2019-2025
29 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $1,034 · 2023: $1,406 · 2024: $2,820 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,712 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,712.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,527.18 | 2022-2025 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $694.39 | 2024-2025 | Cobenfy |
| Abbvie INC. | $673.33 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $553.97 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $491.14 | 2024-2025 | Auvelity |
| Alkermes, INC. | $419.18 | 2021-2025 | Lybalvi |
| Genzyme Corporation | $368.50 | 2022-2025 | |
| Novo Nordisk INC | $279.94 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $264.13 | 2023 | Rebyota |
| Alexion Pharmaceuticals, INC. | $258.82 | 2024 | |
| Viiv Healthcare Company | $249.98 | 2024 | Apretude, Dovato |
| Indivior INC. | $223.87 | 2021-2025 | Sublocade |
| Biogen, INC. | $199.99 | 2022-2023 | Spinraza |
| Gilead Sciences, INC. | $180.34 | 2024 | Vemlidy, Descovy |
| Alnylam Pharmaceuticals INC. | $145.88 | 2022-2023 | Givlaari |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $130.60 | 2025 | Aptima |
| Phathom Pharmaceuticals, INC. | $125.02 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $124.99 | 2023 | Gvoke Hypopen |
| Sk Life Science, INC. | $124.99 | 2023 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $124.97 | 2025 | Uzedy |
| Sage Therapeutics, LLC | $110.87 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $106.91 | 2024 | Arcalyst |
| Pfizer INC. | $99.99 | 2022 | |
| Exact Sciences Corporation | $98.66 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $88.33 | 2025 | Inspire |
| Edwards Lifesciences Corporation | $87.56 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Neurelis, INC. | $64.44 | 2024 | Valtoco |
| Abbott Laboratories | $34.54 | 2023 | Accent, Aveir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.